Sai Parenterals Ltd — earnings calls
1 quarter summarised from transcripts filed with the exchange, every statement cited. Newest first.
Q1 FY27 — transcript filed; not yet summarisedQ4 FY26
Q4 FY26 earnings call
Sai Parenterals reported its first earnings call as a listed company, discussing FY26 results and the acquisition of Australia-based Noumed Pharmaceuticals completed on 12th November 2025. Standalone FY26 revenue grew 30% to about INR162 crore while consolidated revenue rose to INR381 crore including partial-year Noumed contribution. Management outlined a INR440 crore capex program across India and Australia and set out targets for FY27 revenue and EBITDA margin.